ÂÜÀòÂÒÂ×

Erez Bublil has a diverse work experience in the field of pharmaceutical research and development. Erez started their career in 2001 at Tel Aviv University, where they pursued their PhD until 2006. Erez then joined the Weizmann Institute of Science as a Research Senior Intern from 2006 to 2010. In 2011, they worked at Orphan Technologies and the University of Colorado Denver, focusing on pharmaceutical research and drug development. Since 2014, they have been associated with Neopharm Group, initially serving as the Senior Director of Research and Development at Neopharm Life Science Ventures. Currently, they hold the position of Vice President of Research and Development and Chief Scientific Officer at Neopharm Group.

Erez Bublil began their education in 1996 at Tel Aviv University, where they pursued a Bachelor of Science degree in Biology. From 1999 to 2001, they continued their studies at Tel Aviv University and obtained a Master of Science degree focusing on Cancer therapeutics, Cell research, and immunology. Later, from 2001 to 2006, Erez pursued a PhD at Tel Aviv University, specializing in developing an HIV vaccine. After completing their PhD, Erez furthered their education at the Weizmann Institute of Science from 2006 to 2010 as a postdoctoral researcher, focusing on Cancer Research.